Latest news with #orthopedicSurgery
Medscape
13 hours ago
- Health
- Medscape
IV Dexamethasone Cuts Postblock Pain After Hand Surgery
TOPLINE: In patients undergoing elective orthopedic wrist and hand surgery, IV administration of 0.11 mg/kg of dexamethasone before the operation significantly reduced the occurrence and severity of rebound pain after the resolution of the supraclavicular brachial plexus blockade and decreased the use of opioid analgesia. METHODOLOGY: Researchers conducted a prospective randomized trial at a Korean medical center between May 2022 and September 2023 to evaluate the effect of IV dexamethasone on rebound pain in 56 adults undergoing elective orthopedic wrist and hand surgery under supraclavicular brachial plexus blockade. The patients were randomly assigned to receive a 10 mL solution of either 0.11 mg/kg dexamethasone (n = 28; mean age, 49 years; 57% women) or 0.9% saline (control group; n = 28; mean age, 54.5 years; 46% women). Following the administration of a mixture of local anesthetics, dexamethasone or saline was administered immediately after the block. The primary outcome was the difference in worst pain scores before the block and within 12 hours after its resolution. Secondary outcomes were the incidence of rebound pain (defined as the sudden occurrence of severe pain with a numeric rating scale score ≥ 7 at the site of surgery after resolution of the block), cumulative consumption of opioids, and block-related complications. TAKEAWAY: The patients in the control group had a larger difference in pain scores — which the researchers calculated as the worst pain score within 12 hours of the resolution of the block minus the pain score before the block resolved — than those in the dexamethasone group (mean, 7.3 vs 4.7; mean difference between groups, 2.6; P < .001). Rebound pain occurred more frequently in the control group than in the dexamethasone group (79% vs 32%; P < .001); severity of pain at rest and on mobilization was higher in the control group at 6 and 12 hours (P < .001 for both) but not at 24 hours after surgery. The cumulative consumption of opioids was significantly lower in the dexamethasone group than in the control group at 6, 12, and 24 hours after surgery (P < .001 for all). The dexamethasone group reported significantly higher satisfaction and better quality of sleep than the control group, with no block-related complications in either group. IN PRACTICE: 'Intravenous dexamethasone effectively mitigates rebound pain after SCBPB [supraclavicular brachial plexus blockade], ensuring a smoother transition from dense blockade to systemic analgesia,' the researchers reported. SOURCE: This study was led by RyungA Kang, MD, PhD, and Yu Jeong Bang, MD, of Sungkyunkwan University School of Medicine in Seoul, Republic of Korea. It was published online on June 20, 2025, in Canadian Journal of Anesthesia. LIMITATIONS: This study was conducted at a single center and had a relatively small sample size, limiting the generalizability of the findings. The results might vary with combinations of local anesthetics other than the ones used in this study (2% lidocaine and 0.75% ropivacaine with epinephrine). The dose and timing of administration of dexamethasone was selected based on a prior meta-analysis, but the optimal strategy to prevent rebound pain remained undefined. DISCLOSURES: This study did not receive any specific funding. The authors declared having no potential conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Free Malaysia Today
14-05-2025
- Health
- Free Malaysia Today
How robotic arms are revolutionising knee and joint replacements
Pantai Hospital Kuala Lumpur consultant orthopaedic surgeon Dr Rizal Abdul Rani leading a demonstration of the Mako SmartRobotics system. (Moganraj Villavan @ FMT Lifestyle) PETALING JAYA : When a medical checkup revealed she would require knee replacement surgery, retiree Sally Lim was understandably apprehensive. Since last May, she had been plagued by persistent knee pain, sometimes so debilitating she was rendered immobile. X-rays confirmed she was suffering from stage-four osteoarthritis. To manage the condition, Lim first pursued alternative treatments such as gel injections and analgesics, but these only offered fleeting relief. Her turning point came after she discovered that Pantai Hospital Kuala Lumpur offers Mako robotic-assisted surgery – a groundbreaking innovation in the field of joint replacement. 'I remember being very impressed when I first saw the robotic arm. It looked like something straight out of a medical drama,' Lim told FMT Lifestyle. 'I did some research and learnt that this method involves less post-operative pain due to its precision, and recovery times are significantly shorter. I can attest that all this is true.' Lim's surgery was performed by Dr Sivananthan Kanagarayar, who has been a consultant orthopedic surgeon at the hospital since 2009. Lim's operation was successfully performed by Dr K Sivananthan, assisted by the Mako SmartRobotics system. According to Sivananthan, traditional joint-replacement techniques have existed for over 70 years, primarily developed in the United States and the United Kingdom. In Malaysia, such procedures were first introduced during the 1980s. These methods, he explained, had been instrumental in alleviating the pain of patients who suffered from conditions such as arthritis, which was sometimes so intense it disrupted their daily lives. 'Conventionally, joint replacement requires us to make bone cuts to accommodate the implants. These cuts are usually guided by jigs (a type of template or guide used to ensure accurate bone preparation for surgery), which must be rotated with meticulous precision – sometimes by just two or three degrees. 'While traditional methods yield fairly satisfactory results, there can occasionally be complications, such as excessive ligament release when the knee is straightened. With robotic assistance, we can significantly mitigate such risks.' Mako SmartRobotics systems use advanced real-time 3D imaging and robotic guidance to create personalised surgical plans tailored to each patient, allowing for optimal implant placement. The procedure is especially suited for partial or total knee replacement, as well as hip replacement surgery. Mako SmartRobotics systems use advanced real-time 3D imaging and robotic guidance to create personalised surgical plans tailored to each patient. (Moganraj Villavan @ FMT Lifestyle) In Lim's case, Sivananthan conducted a specialised CT scan of her leg, which was sent to the Mako unit in the US. Upon receiving their comprehensive report, he collaborated with a Mako technician to plan out the operation. 'On the day of the surgery, this data is mapped onto the patient's knee, and the bone cuts are made with robotic assistance. The level of precision surpasses the capability of the human eye. 'Moreover, the robot is equipped with haptic feedback technology, preventing it from making incisions beyond the predetermined boundaries,' he explained. According to him, surgeons traditionally rely on mechanical alignment to match the knee replacement with the hip and ankle. Today, thanks to a concept known as kinematic alignment, robots can perform this task with significantly higher accuracy. Sivananthan emphasised that while the Mako robotic arm enhances precision, it is still the expertise of skilled surgeons that ensures the success of the procedure. 'In my experience, patients who undergo robotic-assisted surgery often return to their normal routines more swiftly and express high satisfaction with the results,' he added. The Mako system being tested on a model of a human leg. (Moganraj Villavan @ FMT Lifestyle) Sivanathan further underscored the importance of post-operative physiotherapy, typically spanning three months, to achieve full recovery and optimal joint function. While knee replacement is more commonly associated with elderly patients, he pointed out that he has operated on individuals across a wide age range. He advises consulting a medical professional if routine activities became challenging, or if long-distance walking grows increasingly painful. It has now been seven months since Lim underwent surgery, and she is thrilled to report that her chronic knee pain is a thing of the past. 'The doctor told me, 'If you can bend your knee to 90 degrees within six weeks, you can start driving again.' I was determined to do it. Now, I can drive again,' Lim said, smiling. 'My advice? Trust your doctor, do your homework, and take the leap. You might reclaim the quality of life you thought you'd lost.' For more information, check out Pantai Hospital Kuala Lumpur's website.
Associated Press
06-05-2025
- Business
- Associated Press
Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ('Monogram' or the 'Company'), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones. A press release detailing these results will be issued prior to the call. Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call webcast, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Date: Wednesday, May 14, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Registration Link: The conference call webcast will be broadcast live and available for replay at the investor relations section of the Company's website here. About Monogram Technologies Inc. Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances. The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation. To learn more, visit Investor Relations Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 [email protected] SOURCE: Monogram Technologies Inc. press release
